Discover
ZBIO
Zenas BioPharma, Inc.
28.00
2 x 20.62
2 x 32.61
bid
ask
+
2.62
10.32%
2 @ 04:00 PM
28.00 +0.00 (0.00%)
| Ytd | -22.89% | |
| 1y | 173.97% |
25.48
day range
28.95
8.91
52 week range
44.60
| Open | 25.49 | Prev Close | 25.38 | Low | 25.48 | High | 28.95 | Mkt Cap | 1.77B |
| Vol | 2.24M | Avg Vol | 708.64K | EPS | -9.10 | P/E | N/A | Forward P/E | -12.36 |
| Beta | N/A | Short Ratio | 18.70 | Inst. Own | 90.37% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 19.67 | 200-d Avg | 24.86 | 1yr Est | 42.13 |
| Income Statement | |||
| Operating Expenses | 77.35M | ||
| Research and Development Expense | 60.44M | ||
| Selling, General and Administrative Expense | 16.91M | ||
| Operating Income | -77.35M | ||
| Interest Expense | 6.63M | ||
| Net Income | -80.99M | ||
| Net Income Common Stock | -80.99M | ||
| Net Income Common Stock (USD) | -80.99M | ||
| Consolidated Income | -80.99M | ||
| Earnings per Basic Share | -1.46 | ||
| Earnings per Basic Share (USD) | -1.46 | ||
| Earnings per Diluted Share | -1.46 | ||
| Earning Before Interest & Taxes (EBIT) | -74.36M | ||
| Earning Before Interest & Taxes (USD) | -74.36M | ||
| Weighted Average Shares | 55.62M | ||
| Weighted Average Shares Diluted | 55.62M | ||
| Balance Sheet | |||
| Cash and Equivalents | 500.22M | ||
| Cash and Equivalents (USD) | 500.22M | ||
| Investments | 218.32M | ||
| Investments Current | 216.98M | ||
| Investments Non-Current | 1.34M | ||
| Current Assets | 730.16M | ||
| Property, Plant & Equipment Net | 1.12M | ||
| Total Assets | 747.68M | ||
| Debt Current | 1.04M | ||
| Total Debt | 266.83M | ||
| Current Liabilities | 61.16M | ||
| Debt Non-Current | 265.79M | ||
| Total Liabilities | 411.85M | ||
| Accumulated Retained Earnings (Deficit) | -846.11M | ||
| Accumulated Other Comprehensive Income | -377.00K | ||
| Shareholders Equity | 335.83M | ||
| Shareholders Equity (USD) | 335.83M | ||
| Assets Non-Current | 17.52M | ||
| Total Debt (USD) | 266.83M | ||
| Liabilities Non-Current | 350.69M | ||
| Trade and Non-Trade Payables | 8.94M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 270.00K | ||
| Net Cash Flow from Financing | 433.48M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 389.58M | ||
| Capital Expenditure | -2.00K | ||
| Issuance (Purchase) of Equity Shares | 166.45M | ||
| Issuance (Repayment) of Debt Securities | 267.03M | ||
| Net Cash Flow from Investing | 31.61M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 31.61M | ||
| Net Cash Flow from Operations | -75.20M | ||
| Effect of Exchange Rate Changes on Cash | -311.00K | ||
| Share Based Compensation | 9.20M | ||